Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Laura Espinosa

Internal Medicine Simpsonville, SC Medical Doctor

NPI 1902065915 CMS profile 987035

727 Se Main St Ste 300, Simpsonville, SC 29681

Open in the dashboard

General payments

$2,972

167 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Espinosa of Simpsonville, SC is reported in the CMS Open Payments database as having received $2,972 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $742 41
2024 General $759 42
2023 General $921 53
2022 General $549 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Espinosa
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Laura Espinosa were reported at $742. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Laura Espinosa Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $549 $141 $42–$496 $149
2023 $921 $149 $45–$519 $160
2024 $759 $154 $47–$537 $164
2025 $742 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $576 34 payments
  2. Lilly USA, LLC $560 33 payments
  3. AbbVie, Inc. $297 20 payments
  4. Novartis Pharmaceuticals Corporation $186 10 payments
  5. GlaxoSmithKline, LLC. $164 9 payments
  6. Abbott Laboratories $154 7 payments
  7. Sanofi-Aventis U.S. LLC $149 7 payments
  8. Dexcom, Inc. $111 5 payments
  9. Xeris Pharmaceuticals, Inc. $92 5 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $84 4 payments
  11. Other $598 33 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,907 165 payments
  2. Education $65 2 payments
Products named General payments · program years 2022–2025
  1. Ozempic $421 24 payments
  2. RYBELSUS $349 21 payments
  3. MOUNJARO $317 21 payments
  4. QULIPTA $223 14 payments
  5. JARDIANCE $182 8 payments
  6. UBRELVY $158 11 payments
  7. Tresiba $152 9 payments
  8. LEQVIO $115 6 payments
  9. TZIELD $115 5 payments
  10. SHINGRIX $111 6 payments
  11. Other $1,715 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

3,850

Median for Internal Medicine: 777

Drug cost

$338,949

Median for Internal Medicine: $73,373

Branded share of claims

19%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 87 $78,742
Ozempic Semaglutide Brand 34 $64,870
Januvia Sitagliptin Phosphate Brand 19 $25,057
Mounjaro Tirzepatide Brand 24 $24,039
Rybelsus Semaglutide Brand 15 $23,671
Trulicity Dulaglutide Brand 14 $20,664
Eliquis Apixaban Brand 22 $18,908
Xarelto Rivaroxaban Brand 13 $11,275
Linzess Linaclotide Brand 13 $8,679
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $8,152

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$92,688

Of which drugs: $8,241

Medicare patients

207

Average age 76

Services billed

1,898

138 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Chronic kidney disease 36%
Diabetes 30%
Ischemic heart disease 26%
Depression 25%
Osteoporosis 22%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 12 12 $3,496
Vaccine for influenza for injection into muscle 90662 Office 33 33 $2,700
Sarscv2 vac 30mcg trs-suc im 91320 Office 13 13 $1,986

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $156
$156 24 —
JARDIANCE
  • Lilly USA, LLC $89
$89 87 —
Ozempic
  • Novo Nordisk Inc $61
$61 34 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $50
$50 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record